Last reviewed · How we verify
SUCROSE
Sucrose is a marketed drug primarily indicated for Iron Deficiency Anemia in CKD patients on hemodialysis, with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and indication for a specific patient population. The primary risk is the potential increase in competition as the key patent approaches expiration in 2028.
At a glance
| Generic name | SUCROSE |
|---|---|
| Drug class | Parenteral Iron Replacement [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Iron Deficiency Anemia in CKD on Hemodialysis
Common side effects
- Headache
- Respiratory tract viral infection
- Peritonitis
- Vomiting
- Pyrexia
- Dizziness
- Cough
- Nausea
- Arteriovenous fistula thrombosis
- Hypotension
- Hypertension
- Cardiac failure congestive
Serious adverse events
- Anaphylactic-type reactions
- Angioedema
- Convulsions
- Shock
- Acute myocardial ischemia
- Myocardial infarction
- Bronchospasm
- Dyspnea
- Loss-of-consciousness
- Collapse
Drug interactions
- oral iron preparations
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study) (PHASE2)
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- pH1N1 Blinded Challenge Study (PHASE1)
- Evaluating the Safety and Immunogenicity of MTBVAC (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUCROSE CI brief — competitive landscape report
- SUCROSE updates RSS · CI watch RSS